Evidence map›Paper›PMID 39391712›Full record

ArticleEuropean heart journal open2024

CTG repeat length underlying cardiac events and sudden death in myotonic dystrophy type 1.

Hideki Itoh, Takashi Hisamatsu, Kazuhiko Segawa, Toshiaki Takahashi, Takumi Sato, Hiroto Takada, Satoshi Kuru, Chizu Wada, Mikiya Suzuki, Takuhisa Tamura and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hideki ItohDivision of Patient Safety, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
Takashi HisamatsuDepartment of Public Health, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan.ORCID https://orcid.org/0000-0002-6244-1763
Kazuhiko SegawaDepartment of Cardiology, National Center Hospital, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8551, Japan.
Toshiaki TakahashiDepartment of Neurology, NHO Sendai Nishitaga Hospital, 2-11-11 Kagitorihoncho, Taihaku-ku, Sendai 982-8555, Japan.
Takumi SatoDepartment of Pediatrics, NHO Hirosaki General Medical Center, 1 Tominochou, Hirosaki, Aomori 036-8545, Japan.
Hiroto TakadaDepartment of Neurology, NHO Aomori National Hospital, 155-1 Namioka-Megasawa-Hirano, Aomori 038-1331, Japan.
Satoshi KuruDepartment of Neurology, NHO Suzuka National Hospital, 3-2-1 Kasado, Suzuka, Mie 513-8501, Japan.
Chizu WadaDepartment of Neurology, NHO Akita National Hospital, 84-40 Idonosawa, Uchimichikawa, Iwaki, Yurihonjo, Akita 018-1393, Japan.
Mikiya SuzukiDepartment of Neurology, NHO Higashisaitama Hospital, 4147 Kurohama, Hasuda, Saitama 349-0196, Japan.
Takuhisa TamuraDepartment of Neurology, NHO Higashisaitama Hospital, 4147 Kurohama, Hasuda, Saitama 349-0196, Japan.
Shugo SuwazonoDepartment of Neurology and Center for Clinical Neuroscience, NHO Okinawa National Hospital, 3-20-14 Ganeko, Ginowan, Okinawa 901-2214, Japan.
Koichi KimuraDepartment of Laboratory Medicine/Cardiology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.
Tsuyoshi MatsumuraDepartment of Neurology, NHO Osaka Toneyama Medical Center, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552, Japan.
Masanori P TakahashiDepartment of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita, Osaka 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Myotonic dystrophy Type 1 (DM1) is caused by the expansion of CTG repeats (CTGn) in the DM1 protein kinase (DMPK) gene, while it remains unclear whether CTGn may be associated with the incidence of cardiac events or sudden death in Japan as well as Europe. The aim of this study was to investigate the association between CTGn and cardiac involvements. Methods and results: This cohort study included patients with DM1 who were retrospectively recruited from nine Japanese hospitals specializing in neuromuscular diseases. A total of 496 patients with DM1 who underwent a genetic test in the DMPK gene were analysed. Patients with congenital form or under 15 years old were excluded and patients were assigned into the quartiles. When we compared the incidence of cardiac events including advanced/complete atrioventricular block, pacemaker implantation, and ventricular tachycardias or mortality among four groups, patients with 1300 or longer CTGn experienced composite cardiac events [hazard ratio (HR): 3.19, 95% confidence interval (CI): 1.02-9.99, Conclusion: Regarding the cardiac events and mortality in patients with DM1, patients with 1300 or longer CTGn are at especially high risk.

Indexed as

Conduction diseaseMyotonic dystrophySudden death

Identifiers

PMID39391712
PMCPMC11465163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.